Balancing Clots and Bleeding: Anticoagulation Challenges Across Mechanical Circulatory Support

Patients whose failing hearts are kept alive by machines face a paradox that has defined cardiovascular critical care for decades: the very anticoagulant drugs that keep blood from clotting inside pumps and oxygenators can also cause dangerous, sometimes fatal, bleeding. A new narrative review published in Cardiology and Therapy examines how clinicians navigate this trade-off across the major mechanical circulatory support platforms, from extracorporeal membrane oxygenation (ECMO) to durable left ventricular assist devices, and where the evidence still falls short.

The scale of the competing risks is stark. In patients supported with ECMO, bleeding complications occur in approximately 30 percent of patients and thrombotic complications in approximately 21 percent, according to the review, with both contributing substantially to morbidity, circuit exchange, and mortality. The extracorporeal circuit exposes blood to nonendothelial surfaces that trigger contact activation, while systemic anticoagulation, acquired coagulopathy, platelet dysfunction, and shear-mediated loss of high-molecular-weight von Willebrand factor multimers drive bleeding on the other side of the balance. Veno-venous ECMO is generally associated with lower bleeding and vascular complication rates than veno-arterial support, because it relies exclusively on venous cannulation and avoids large-bore arterial access, and because veno-arterial patients often present with cardiogenic shock, cardiac arrest, or post-cardiotomy shock, conditions that compound coagulopathy.

Against that backdrop, the choice of anticoagulant and the way it is monitored matter enormously. Unfractionated heparin retains its dominant position because of its short half-life, rapid reversibility, and the depth of accumulated clinical experience with it. Current guidance from the International Society on Thrombosis and Hemostasis suggests anti-factor Xa targets of approximately 0.3 to 0.5 IU/mL for ECMO, while the 2021 Extracorporeal Life Support Organization guideline recommends a broader range of 0.3 to 0.7 IU/mL. The activated partial thromboplastin time remains widely used, either alone or in combination with anti-factor Xa assays, but the review emphasizes that aPTT can be distorted by inflammation, hepatic dysfunction, lupus anticoagulants, and consumptive coagulopathy, making assay discordance a persistent challenge that favors individualized, integrated monitoring rather than reliance on any single test.

Direct thrombin inhibitors, particularly bivalirudin, have emerged as the principal alternative for patients with heparin-induced thrombocytopenia or heparin resistance. Systematic reviews, meta-analyses, and observational studies suggest that bivalirudin may be associated with lower rates of major bleeding, reduced circuit thrombosis, and improved time within the therapeutic anticoagulation range compared with heparin in selected ECMO populations. The review is careful, however, to flag the evidentiary ceiling: these findings derive predominantly from retrospective and non-randomized studies, and adequately powered randomized controlled trials comparing bivalirudin with unfractionated heparin remain unavailable, so definitive superiority has not been established. Choice of agent within the class also follows organ function, with argatroban generally preferred in significant renal dysfunction because of its hepatic clearance, and bivalirudin potentially preferred in hepatic impairment because it is cleared predominantly by proteolytic metabolism and renal elimination.

One of the most consequential recent randomized findings concerns how little anticoagulation some ECMO patients may actually need. The RATE trial demonstrated that low-dose unfractionated heparin and therapeutic low-molecular-weight heparin were non-inferior to standard-dose unfractionated heparin for a primary composite clinical endpoint in selected adult patients receiving veno-venous or veno-arterial ECMO without another indication for full-dose anticoagulation. The review nonetheless cautions that, given patient heterogeneity, institutional variability in monitoring, and uncertainty about optimal targets, such lower-intensity approaches should remain individualized rather than routinely applied to everyone on the circuit. Lower-intensity strategies may be appropriate in carefully selected patients at high bleeding risk, but the supporting evidence base is still described as limited.

Device-specific practice varies widely, and the review devotes detailed attention to each platform. For the CentriMag temporary ventricular assist system, the 2023 ISHLT/HFSA guideline on acute mechanical circulatory support recommends withholding systemic anticoagulation for roughly 6 to 12 hours after implantation with cardiopulmonary bypass until hemostasis is achieved, then titrating intravenous heparin to an aPTT of 60 to 80 seconds or an activated clotting time of 160 to 180 seconds, with higher targets considered as postoperative bleeding risk declines. For the TandemHeart percutaneous ventricular assist device, heparin is recommended before implantation targeting an activated clotting time of approximately 250 to 300 seconds, followed by titration to an aPTT of 65 to 80 seconds, an activated clotting time of 180 to 220 seconds, or an anti-factor Xa level of approximately 0.3 to 0.7 IU/mL. Bleeding rates approaching 45 percent have been reported with ProtekDuo right ventricular support, and device-specific anti-factor Xa targets have not been established for CentriMag, leaving much practice extrapolated from ECMO experience.

Among the most concrete recent advances are bicarbonate-based purge solutions for Impella microaxial pumps. The purge system protects the device motor by maintaining a pressure barrier, but the heparin it contains contributes to systemic anticoagulation, complicating total dose accounting. In April 2022, the US Food and Drug Administration authorized sodium bicarbonate-based purge solutions for left-sided Impella and Impella RP systems as an alternative for patients in whom heparin is contraindicated, and labeling modifications in February 2026 further expanded that indication at the treating physician’s clinical judgment. Case reports, case series, and observational studies demonstrate feasibility in carefully selected patients, including those with heparin-induced thrombocytopenia or significant bleeding concerns, but comparative evidence remains limited, and the review positions bicarbonate purge as an important option for selected patients rather than a routine replacement for heparin-containing purge solutions.

For durable left ventricular assist devices, the randomized ARIES-HM3 trial has reshaped antiplatelet practice: omission of aspirin reduced nonsurgical bleeding without increasing thromboembolic events, supporting warfarin monotherapy in carefully selected HeartMate 3 recipients without another indication for antiplatelet therapy. Interest has also grown in direct oral anticoagulants, particularly apixaban, with systematic reviews, meta-analyses, and small randomized feasibility studies including DOT-HM3 and DOAC-LVAD suggesting apixaban may be feasible in selected HeartMate 3 recipients, potentially with lower bleeding rates. The review is emphatic, however, that this evidence consists predominantly of small observational studies and trials not adequately powered to establish non-inferiority, so vitamin K antagonists remain the standard of care and direct oral anticoagulants should be considered investigational until larger prospective trials are available. Postoperatively, heparin is typically initiated within 12 to 24 hours of implantation and transitioned to warfarin titrated to an international normalized ratio of 2.0 to 3.0, with some HeartMate 3 programs favoring a narrower range of 2.0 to 2.5.

The review also maps the management of heparin-induced thrombocytopenia and heparin resistance. When heparin-induced thrombocytopenia is suspected with intermediate or high clinical probability, American Society of Hematology guidelines recommend promptly starting a non-heparin anticoagulant, most commonly bivalirudin or argatroban, without waiting for confirmatory testing, and discontinuing every source of heparin, including purge solutions and flushes. For Impella patients, guidance supports switching to a bicarbonate-based purge while continuing systemic direct thrombin inhibitor therapy, since these agents should not be added directly to the purge. Heparin resistance, defined functionally as failure to achieve therapeutic anticoagulation despite appropriate dosing, is often driven by reduced antithrombin activity from consumption, hemodilution, inflammation, or circuit losses; the 2023 ISTH communication distinguishes true resistance from altered heparin responsiveness, and while some centers supplement antithrombin, the optimal threshold and its impact on outcomes remain uncertain.

Looking forward, the authors identify substantial knowledge gaps: adequately powered randomized comparisons of heparin versus direct thrombin inhibitors, randomized evaluations of bicarbonate versus heparin-containing purge solutions, device-specific targets for ProtekDuo and Impella RP, and prospective trials of direct oral anticoagulants in durable devices. Emerging strategies targeting the contact activation pathway, including factor XI and factor XII inhibition, are described as promising but investigational. The review also highlights the role of pharmacists within multidisciplinary teams, noting a recent multicenter study in which pharmacist-managed warfarin therapy in HeartMate 3 recipients was associated with significantly greater time in the therapeutic range than usual care, although differences in major clinical outcomes were not observed. The overall message is that anticoagulation in mechanical circulatory support is becoming more individualized and more sophisticated, but the evidence base still lags well behind the pace of practice.

Subject of Research: Anticoagulation strategies, monitoring, and device-specific management across mechanical circulatory support platforms

Article Title: Anticoagulation in Mechanical Circulatory Support: Contemporary Challenges and Future Directions in Cardiovascular Pharmacotherapy

Article References: Alfehaid, L., Alomran, M., Althobaiti, A., Alshehri, A., Bahmaid, R., & Albulushi, A. (2026). Anticoagulation in Mechanical Circulatory Support: Contemporary Challenges and Future Directions in Cardiovascular Pharmacotherapy. Cardiology and Therapy. https://doi.org/10.1007/s40119-026-00480-6

Image Credits: AI Generated

DOI: 10.1007/s40119-026-00480-6

Keywords: mechanical circulatory support, ECMO, anticoagulation, unfractionated heparin, bivalirudin, anti-factor Xa monitoring, Impella, left ventricular assist device, heparin-induced thrombocytopenia, ARIES-HM3 trial, hemocompatibility, cardiogenic shock